NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, ...
Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback